-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) is one of the most influential international conferences in the field of blood disease treatment.
The 47th EBMT annual meeting in 2021 will be held in the form of an online virtual conference on March 14-17.
Covers major developments related to hematopoietic stem cell transplantation and cell therapy research.
With the advancement and innovation of medical technology, China is also playing an increasingly important role in the world's medical field.
More and more Chinese experts are showing their demeanor at international conferences.
A total of 2 Oral and 10 Posters are shortlisted for the 2021 EBMT Annual Conference.
.
Today, we will take stock of 10 wonderful reports from Poster.
01 Abstract Number: P054 Title: PD-1 upregulation on peripheral CD8+ CD45RA+ CCR7+ T cells of donors primed by G-CSF may alleviate acute Graft-Versus-Host Disease after allo-HSCT.
Speaker: D.
Liu Unit: Peking University Blood The conclusion of the brief study by the Institute of Disease Research: Granulocyte colony stimulating factor (G-CSF) can up-regulate the expression of PD-1 in donor’s peripheral blood CD8+ CD45RA+ CCR7+ T cells, which may help to reduce allogeneic hematopoietic stem cell transplantation (alloHCT) The severity of acute graft-versus-host disease (aGVHD).
Evaluating the expression level of PD-1 on peripheral CD8+ CD45RA+ CCR7+ T cells may help to select a suitable donor that can reduce the alloHCT post-aloHCT reaction.
02 Abstract Number: P086 Title: Basiliximab for the treatment of patients with steroid refractory acute Graft Versus Host Disease: literature review and pooled analysis.
Speaker: Mo Xiaodong Unit: Peking University People’s Hospital Brief conclusion of the study: The results of the pooled analysis show that Basiliximab The response rate of (Basiliximab) in glucocorticoid-resistant (SR) aGVHD is consistent with previous studies.
The overall response rate (ORR) reported in the literature is> 70%.
Therefore, basiliximab may be a potential treatment for SR-aGVHD.
However, due to lack of data, the aggregate analysis is based only on the results of observational studies, and a larger randomized controlled study (RCT) is needed to verify these findings.
03 Abstract No.
: P073 Title: Elevated REG3α predicts refractory aGVHD in patients who received steroids- ruxolitinib as the first line therapy.
Speaker: D.
Liu Unit: Chinese People’s Liberation Army General Hospital (301 Hospital) Brief conclusion of the study: High-risk (based on Minnesota aGVHD risk score and MAGIC 2/3 biomarker risk stratification) for aGVHD patients, the new first-line treatment prednisone-rucotinib is a promising option.
The serum concentration kinetics of the biomarker REG3α is related to the treatment response.
Elevated REG3α levels may indicate poor response to treatment and refractory aGVHD.
04 Abstract Number: P086 Title: Efficiency of modified FC/ATG pretreatment in haploid and allogeneic hematopoietic stem cell transplantation for severe Aplastic Anemia.
Speaker: Ma Liangming Unit: Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences) Brief research conclusion: modified FC/ATG The curative effect of the pretreatment program on severe aplastic anemia (SAA) is similar to other pretreatment programs at home and abroad, but with less toxicity and side effects, and a high overall survival (OS) rate.
The haplotype hematopoietic stem cell transplantation (haplo-HSCT) group had a high infection rate of Epstein-Barr virus and CMV virus.
The efficacy of the haplo-HSCT group is similar to that of the MSD-HSCT group, and the haplotype donor can be used as an alternative donor for SAA patients without a matched donor.
05 Abstract Number: P093 Title: Haploidentical stem cell transplantation in AML with t(6;9)(p23; q34); dek-nup214 shows a favourable outcome: single center experience.
Speaker: L.
Liu Unit: Department of Hematology (Langfang) ), a brief research conclusion of the Institute of Hematology (Beijing): Single-center data show that AML patients with t(6;9) have obvious clinicopathological characteristics, which are characterized by frequent multi-line pathological hematopoiesis and the presence of myeloid markers , Common FLT3-ITD exist at the same time.
All 14 t(6;9)(p23;q34) patients who received haplo-HSCT survived the follow-up period, which seems to be better than the allo-HSCT results previously reported in AML patients (2-year OS: 61%).
This may be related to the fact that most patients are in complete remission (CR) at the time of transplantation and the strong anti-leukemia effect of haplo-HSCT.
Considering the small number of patients, this conclusion needs further research and verification.
06 Abstract Number: P137 Title: Haploidentical hematopoietic stem cell transplantation for Malignant Infantile Osteopetrosis and Intermediate Osteopetrosis: a retrospective analysis of a single-center.
Speaker: G.
Zhu Unit: Beijing Children’s Hospital of Capital Medical University Brief conclusion of the study: Figure 5 The annual OS rate is 73.
9%.
Compared with MIOP and IOP, there was no statistically significant difference between the two (73.
9% vs 100.
0%, P=0.
2444).
Haplo-HSCT is effective for malignant pediatric bone sclerosis (MIOP) and IOP, with a high survival rate and significant improvement in clinical symptoms.
For patients with visual impairment before HSCT, improvement is slow after transplantation.
The incidence of GVHD is high but mild, and can be effectively controlled by appropriate treatment.
These data indicate that haplo-HSCT is feasible in the treatment of MIOP and IOP when HLA-matched sibling donors are not available.
07 Abstract Number: P137 Title: Stem cell transplantation in Mantle Cell Lymphoma: post-transplant outcomes of Taiwan blood and marrow transplantation registry.
Speaker: Y.
-H.
Wang Unit: National Taiwan University Hospital Brief study conclusion: This study proves Early consolidation of autologous hematopoietic stem cell transplantation (auto-HSCT) can bring good progression-free survival (PFS) and OS to patients with mantle cell lymphoma (MCL), which also proves that blast cell variants and auto-HSCT are 12 months after The impact of internal disease progression (POD12) on the prognosis of Asian patients. At the same time, new drugs may help high-risk patients bridge the subsequent allo-HSCT.
08 Abstract Number: P142 Title: Successful treatment of Hepatosplenic T-cell Lymphoma with intensified myeloablative conditioning regimens followed by unmanipulated haploidentical hematopoietic stem cell transplantation.
Speaker: Zhao Yanli Unit: Lu Daopei Hospital Brief study conclusion: 3 cases of hepatosplenic T-cell lymphoma ( After receiving haplo-HSCT, patients with HSTCL achieved disease-free survival and achieved complete donor mosaicism.
Considering the high risk and poor prognosis of HSTCL, the encouraging clinical results of this study indicate that enhanced myeloablative pretreatment haplo-HSCT can be considered as a safe and effective treatment for HSTCL.
09 Abstract Number: P150 Title: Pegylated G-CSF versus G-CSF following HD-CTX for PBSC mobilization and hematopoietic reconstitution after ASCT in newly diagnosed Multiple Myeloma patients.
Speaker: Meilan Chen Unit: The First Affiliated Hospital of Sun Yat-Sen University : In terms of peripheral blood stem cell (PBSC) mobilization and hematopoietic reconstruction after auto-HSCT in newly diagnosed multiple myeloma (NDMM) patients, high-dose cyclophosphamide (HD-CTX) + pegylated granulocyte colony stimulating factor (PEG-G-CSF) is as effective as HD-CTX+G-CSF, but with less toxicity and side effects.
Moreover, PEG-G-CSF can reduce the time for neutrophil and platelet implantation after transplantation.
10 Abstract Number: P152 Title: Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed Multiple Myeloma.
Reporter: Jingli Gu Unit: The First Affiliated Hospital of Sun Yat-sen University Brief research conclusion: Recombinant human thrombopoietin ( rhTPO) can promote platelet implantation after auto-HSCT in NDMM patients, and has good tolerability and long-term safety, especially for patients with low CD34+ cell counts after reinfusion.
After auto-HSCT in NDMM patients, early rhTPO may be recommended.
Reference source: 2021 EBMT conference official website.
https://ebmt2021.
abstractserver.
com/program/#/details/sessions/432,433,429,431,427,426,425,423,422,421,420,428,419,418,417,430,416,415,414,413,412,411,410,409,408,407,406,403, read the original text
The 47th EBMT annual meeting in 2021 will be held in the form of an online virtual conference on March 14-17.
Covers major developments related to hematopoietic stem cell transplantation and cell therapy research.
With the advancement and innovation of medical technology, China is also playing an increasingly important role in the world's medical field.
More and more Chinese experts are showing their demeanor at international conferences.
A total of 2 Oral and 10 Posters are shortlisted for the 2021 EBMT Annual Conference.
.
Today, we will take stock of 10 wonderful reports from Poster.
01 Abstract Number: P054 Title: PD-1 upregulation on peripheral CD8+ CD45RA+ CCR7+ T cells of donors primed by G-CSF may alleviate acute Graft-Versus-Host Disease after allo-HSCT.
Speaker: D.
Liu Unit: Peking University Blood The conclusion of the brief study by the Institute of Disease Research: Granulocyte colony stimulating factor (G-CSF) can up-regulate the expression of PD-1 in donor’s peripheral blood CD8+ CD45RA+ CCR7+ T cells, which may help to reduce allogeneic hematopoietic stem cell transplantation (alloHCT) The severity of acute graft-versus-host disease (aGVHD).
Evaluating the expression level of PD-1 on peripheral CD8+ CD45RA+ CCR7+ T cells may help to select a suitable donor that can reduce the alloHCT post-aloHCT reaction.
02 Abstract Number: P086 Title: Basiliximab for the treatment of patients with steroid refractory acute Graft Versus Host Disease: literature review and pooled analysis.
Speaker: Mo Xiaodong Unit: Peking University People’s Hospital Brief conclusion of the study: The results of the pooled analysis show that Basiliximab The response rate of (Basiliximab) in glucocorticoid-resistant (SR) aGVHD is consistent with previous studies.
The overall response rate (ORR) reported in the literature is> 70%.
Therefore, basiliximab may be a potential treatment for SR-aGVHD.
However, due to lack of data, the aggregate analysis is based only on the results of observational studies, and a larger randomized controlled study (RCT) is needed to verify these findings.
03 Abstract No.
: P073 Title: Elevated REG3α predicts refractory aGVHD in patients who received steroids- ruxolitinib as the first line therapy.
Speaker: D.
Liu Unit: Chinese People’s Liberation Army General Hospital (301 Hospital) Brief conclusion of the study: High-risk (based on Minnesota aGVHD risk score and MAGIC 2/3 biomarker risk stratification) for aGVHD patients, the new first-line treatment prednisone-rucotinib is a promising option.
The serum concentration kinetics of the biomarker REG3α is related to the treatment response.
Elevated REG3α levels may indicate poor response to treatment and refractory aGVHD.
04 Abstract Number: P086 Title: Efficiency of modified FC/ATG pretreatment in haploid and allogeneic hematopoietic stem cell transplantation for severe Aplastic Anemia.
Speaker: Ma Liangming Unit: Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences) Brief research conclusion: modified FC/ATG The curative effect of the pretreatment program on severe aplastic anemia (SAA) is similar to other pretreatment programs at home and abroad, but with less toxicity and side effects, and a high overall survival (OS) rate.
The haplotype hematopoietic stem cell transplantation (haplo-HSCT) group had a high infection rate of Epstein-Barr virus and CMV virus.
The efficacy of the haplo-HSCT group is similar to that of the MSD-HSCT group, and the haplotype donor can be used as an alternative donor for SAA patients without a matched donor.
05 Abstract Number: P093 Title: Haploidentical stem cell transplantation in AML with t(6;9)(p23; q34); dek-nup214 shows a favourable outcome: single center experience.
Speaker: L.
Liu Unit: Department of Hematology (Langfang) ), a brief research conclusion of the Institute of Hematology (Beijing): Single-center data show that AML patients with t(6;9) have obvious clinicopathological characteristics, which are characterized by frequent multi-line pathological hematopoiesis and the presence of myeloid markers , Common FLT3-ITD exist at the same time.
All 14 t(6;9)(p23;q34) patients who received haplo-HSCT survived the follow-up period, which seems to be better than the allo-HSCT results previously reported in AML patients (2-year OS: 61%).
This may be related to the fact that most patients are in complete remission (CR) at the time of transplantation and the strong anti-leukemia effect of haplo-HSCT.
Considering the small number of patients, this conclusion needs further research and verification.
06 Abstract Number: P137 Title: Haploidentical hematopoietic stem cell transplantation for Malignant Infantile Osteopetrosis and Intermediate Osteopetrosis: a retrospective analysis of a single-center.
Speaker: G.
Zhu Unit: Beijing Children’s Hospital of Capital Medical University Brief conclusion of the study: Figure 5 The annual OS rate is 73.
9%.
Compared with MIOP and IOP, there was no statistically significant difference between the two (73.
9% vs 100.
0%, P=0.
2444).
Haplo-HSCT is effective for malignant pediatric bone sclerosis (MIOP) and IOP, with a high survival rate and significant improvement in clinical symptoms.
For patients with visual impairment before HSCT, improvement is slow after transplantation.
The incidence of GVHD is high but mild, and can be effectively controlled by appropriate treatment.
These data indicate that haplo-HSCT is feasible in the treatment of MIOP and IOP when HLA-matched sibling donors are not available.
07 Abstract Number: P137 Title: Stem cell transplantation in Mantle Cell Lymphoma: post-transplant outcomes of Taiwan blood and marrow transplantation registry.
Speaker: Y.
-H.
Wang Unit: National Taiwan University Hospital Brief study conclusion: This study proves Early consolidation of autologous hematopoietic stem cell transplantation (auto-HSCT) can bring good progression-free survival (PFS) and OS to patients with mantle cell lymphoma (MCL), which also proves that blast cell variants and auto-HSCT are 12 months after The impact of internal disease progression (POD12) on the prognosis of Asian patients. At the same time, new drugs may help high-risk patients bridge the subsequent allo-HSCT.
08 Abstract Number: P142 Title: Successful treatment of Hepatosplenic T-cell Lymphoma with intensified myeloablative conditioning regimens followed by unmanipulated haploidentical hematopoietic stem cell transplantation.
Speaker: Zhao Yanli Unit: Lu Daopei Hospital Brief study conclusion: 3 cases of hepatosplenic T-cell lymphoma ( After receiving haplo-HSCT, patients with HSTCL achieved disease-free survival and achieved complete donor mosaicism.
Considering the high risk and poor prognosis of HSTCL, the encouraging clinical results of this study indicate that enhanced myeloablative pretreatment haplo-HSCT can be considered as a safe and effective treatment for HSTCL.
09 Abstract Number: P150 Title: Pegylated G-CSF versus G-CSF following HD-CTX for PBSC mobilization and hematopoietic reconstitution after ASCT in newly diagnosed Multiple Myeloma patients.
Speaker: Meilan Chen Unit: The First Affiliated Hospital of Sun Yat-Sen University : In terms of peripheral blood stem cell (PBSC) mobilization and hematopoietic reconstruction after auto-HSCT in newly diagnosed multiple myeloma (NDMM) patients, high-dose cyclophosphamide (HD-CTX) + pegylated granulocyte colony stimulating factor (PEG-G-CSF) is as effective as HD-CTX+G-CSF, but with less toxicity and side effects.
Moreover, PEG-G-CSF can reduce the time for neutrophil and platelet implantation after transplantation.
10 Abstract Number: P152 Title: Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed Multiple Myeloma.
Reporter: Jingli Gu Unit: The First Affiliated Hospital of Sun Yat-sen University Brief research conclusion: Recombinant human thrombopoietin ( rhTPO) can promote platelet implantation after auto-HSCT in NDMM patients, and has good tolerability and long-term safety, especially for patients with low CD34+ cell counts after reinfusion.
After auto-HSCT in NDMM patients, early rhTPO may be recommended.
Reference source: 2021 EBMT conference official website.
https://ebmt2021.
abstractserver.
com/program/#/details/sessions/432,433,429,431,427,426,425,423,422,421,420,428,419,418,417,430,416,415,414,413,412,411,410,409,408,407,406,403, read the original text
